1
|
Spalato-Ceruso M, Bouteiller F, Guegan JP, Toulmonde M, Bessede A, Kind M, Cousin S, Buy X, Palussiere J, Le Loarer F, Dadone-Montaudie B, Pulido M, Italiano A. Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study. J Hematol Oncol 2022; 15:157. [PMID: 36303228 PMCID: PMC9609223 DOI: 10.1186/s13045-022-01377-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Accepted: 10/19/2022] [Indexed: 12/01/2022] Open
Abstract
Soft tissue sarcomas (STS) are heterogeneous mesenchymal tumors with limited therapeutic options in the advanced setting. Immune checkpoint inhibitors have been shown to have significant clinical activity in inflamed STS which are characterized by the presence of tertiary lymphoid structures (TLS). New strategies are needed to sensitize TLS-negative STS to immunotherapy. Engagement of the toll-Like Receptor 4 (TLR4) signal pathway contributes to the development of a favorable tumor microenvironment in solid tumors. G100 is a highly potent toll-like receptor 4 (TLR4) agonist. We hypothesized that intra-tumoral G100 would induce a robust local and potentially systemic anti-tumor immune response in the microenvironment of TLS-negative sarcoma, leading to improved response to PD1 inhibition. Twenty metastatic STS patients who had a superficial injectable lesion were treated with 50 mg of cyclophosphamide (CP) orally twice daily (1 week on and 1 week off), 200 mg of pembrolizumab intravenously on day 8 of a planned 21-day cycle and G100 20 µg one weekly intra-tumoral injection for at least 6 weeks and for a maximum of 12 weeks (1st injection one week before CP administration, ie. Day -7). Biopsies and blood were collected pre and post treatment. Of the 17 patients assessable for efficacy analysis, 2 were progression-free at 6 months, and the 6-month non-progression rate was 11.8% (95% CI: 1.5–36.4), indicating that the first endpoint of the study was not reached. In 8 patients, there was an increase in T-cell infiltration into tumor after treatment. The ratio CD8/Fox-P3 + CD4 on treatment decreased in 11 cases out of 14 suggesting a predominant induction of Treg. Soluble PDL1 levels at baseline were also with adverse outcome. G100 appears to modulate the tumor microenvironment with significant infiltration of T cells. However, clinical activity in combination with PD1 inhibition was limited and no clear correlation was observed between tumor shrinkage and increased inflammation. TLR4 stimulation might have both antitumor and pro-tumor consequences. Trial registration: This study was registered with ClinicalTrial.gov, number NCT02406781.
Collapse
Affiliation(s)
- Mariella Spalato-Ceruso
- grid.476460.70000 0004 0639 0505Early Phase Trials Unit, Department of Medicine, Institut Bergonié, 33000 Bordeaux, France
| | - Fanny Bouteiller
- Clinical and Epidemiology Department, Clinical Investigation Centre, Bordeaux, France
| | | | - Maud Toulmonde
- grid.476460.70000 0004 0639 0505Early Phase Trials Unit, Department of Medicine, Institut Bergonié, 33000 Bordeaux, France
| | | | - Michèle Kind
- grid.476460.70000 0004 0639 0505Department of Imaging, Institut Bergonié, Bordeaux, France
| | - Sophie Cousin
- grid.476460.70000 0004 0639 0505Early Phase Trials Unit, Department of Medicine, Institut Bergonié, 33000 Bordeaux, France
| | - Xavier Buy
- grid.476460.70000 0004 0639 0505Department of Imaging, Institut Bergonié, Bordeaux, France
| | - Jean Palussiere
- grid.476460.70000 0004 0639 0505Department of Imaging, Institut Bergonié, Bordeaux, France
| | - François Le Loarer
- grid.476460.70000 0004 0639 0505Department of Pathology, Institut Bergonié, Bordeaux, France
| | | | | | - Antoine Italiano
- grid.476460.70000 0004 0639 0505Early Phase Trials Unit, Department of Medicine, Institut Bergonié, 33000 Bordeaux, France ,grid.412041.20000 0001 2106 639XFaculty of Medicine, University of Bordeaux, Bordeaux, France
| |
Collapse
|
2
|
Lu H, Betancur A, Chen M, Ter Meulen JH. Toll-Like Receptor 4 Expression on Lymphoma Cells Is Critical for Therapeutic Activity of Intratumoral Therapy With Synthetic TLR4 Agonist Glucopyranosyl Lipid A. Front Oncol 2020; 10:1438. [PMID: 32974162 PMCID: PMC7466407 DOI: 10.3389/fonc.2020.01438] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Accepted: 07/07/2020] [Indexed: 11/24/2022] Open
Abstract
Intratumoral (IT) injections of Glucopyranosyl lipid A (G100), a synthetic toll-like receptor 4 (TLR4) agonist formulated in a stable emulsion, resulted in T-cell inflammation of the tumor microenvironment (TME) and complete cure of 60% of mice with large established A20 lymphomas. Strong abscopal effects on un-injected lesions were observed in a bilateral tumor model and surviving mice resisted a secondary tumor challenge. Depletion of CD8 T-cells, but not CD4 or NK cells, abrogated the anti-tumor effect. Unexpectedly, TLR4 knock-out rendered A20 tumors completely non-responsive to G100. In vitro studies showed that GLA has direct effect on A20 cells, but not on A20 cells deficient for TLR4. As shown by genotyping and phenotyping analysis, G100 strongly activated antigen presentation functions in A20 cells in vitro and in vivo and induced their apoptosis in a dose dependent manner. Similarly, the TLR4 positive human mantle cell lymphoma line Mino showed in vitro activation with G100 that was blocked with an anti-TLR4 antibody. In the A20 model, direct activation of B-lymphoma cells with G100 is sufficient to induce protective CD8 T-cell responses and TLR4 expressing human B-cell lymphomas may be amenable to this therapy as well.
Collapse
Affiliation(s)
- Hailing Lu
- Immune Design Corp., Seattle, WA, United States
| | | | | | | |
Collapse
|